Publications by authors named "M Tarantino"
Current treatments for persistent or chronic immune thrombocytopenia (ITP) are limited by inadequate response, toxicity, and impaired quality of life. The Bruton tyrosine kinase inhibitor rilzabrutinib was evaluated to further characterize safety and durability of platelet response. LUNA2 Part B is a multicenter, phase 1/2 study in adults with ITP (≥ 3 months duration, platelet count < 30 × 10/L) who failed ≥ 1 ITP therapy (NCT03395210, EudraCT 2017-004012-19).
View Article and Find Full Text PDFIntroduction: We previously demonstrated that regulating mitochondria-associated endoplasmic reticulum (ER) membranes (MAMs) affects axonal Aβ generation in a well-characterized three-dimensional (3D) neural Alzheimer's disease (AD) model. MAMs vary in thickness and length, impacting their functions. Here, we examined the effect of MAM thickness on Aβ in our 3D neural model of AD.
View Article and Find Full Text PDFBacteria-mediated treatments gained increasing attention as alternative therapies against tumors. An attenuated mutant strain of Salmonella enterica serovar Typhimurium (STMΔznuABC) has recently been considered as a potential new anti-cancer strategy. However, it is unclear whether this activity is tumor-induced or species-specific, and no data are available regarding STMΔznuABC on canine mammary tumors (CMTs).
View Article and Find Full Text PDFArticle Synopsis
- Hemophilia A (HA) is characterized by frequent bleeding episodes, often requiring prophylactic factor VIII (FVIII) replacement to manage, especially when combined with von Willebrand disease (VWD), which is present in around 1% of the population.
- Co-existing HA and mild VWD can complicate effective treatment, and while traditional FVIII/VWF concentrates are used, some patients struggle with adherence due to the intravenous administration method.
- A new alternative, emicizumab, a non-factor subcutaneous therapy, has shown promise in reducing bleeding rates for patients with severe HA and VWD when traditional prophylaxis was insufficient, suggesting it could be a valuable option for better management.
Background: Patients with hereditary antithrombin deficiency (HAD) have an increased risk of venous thromboembolism (VTE). The American Thrombosis and Hemostasis Network (ATHN) 12: HAD Pilot Project established a registry to collect data on patients with HAD.
Objectives: To inform current practice and serve as a platform to design a multicenter global registry for patients with HAD.